Vanda Pharmaceuticals Valuation
Is VNDA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for VNDA?
Other financial metrics that can be useful for relative valuation.
|What is VNDA's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does VNDA's PE Ratio compare to its peers?
|Company||PE||Estimated Growth||Market Cap|
EGRX Eagle Pharmaceuticals
EBS Emergent BioSolutions
ORGO Organogenesis Holdings
CGEM Cullinan Oncology
VNDA Vanda Pharmaceuticals
Price-To-Earnings vs Peers: VNDA is expensive based on its Price-To-Earnings Ratio (68.3x) compared to the peer average (11.3x).
Price to Earnings Ratio vs Industry
How does VNDA's PE Ratio compare vs other companies in the US Biotechs Industry?
Price to Earnings Ratio vs Fair Ratio
What is VNDA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||68.3x|
|Fair PE Ratio||22.5x|
Price-To-Earnings vs Fair Ratio: VNDA is expensive based on its Price-To-Earnings Ratio (68.3x) compared to the estimated Fair Price-To-Earnings Ratio (22.5x).
Share Price vs Fair Value
What is the Fair Price of VNDA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: VNDA ($7.83) is trading below our estimate of fair value ($12.95)
Significantly Below Fair Value: VNDA is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.